Literature DB >> 30923808

Successful Control of Streptococcus pneumoniae 19A Replacement With a Catch-up Primary Vaccination Program in Taiwan.

Chun-Yi Lu1, Chuen-Sheue Chiang2,3, Cheng-Hsun Chiu4,5, En-Tzu Wang2, Ying-Yan Chen2, Shu-Man Yao2, Luan-Yin Chang1, Li-Min Huang1, Tzou-Yien Lin4,5, Jih-Haw Chou2.   

Abstract

BACKGROUND: Streptococcus pneumoniae infections in Taiwan mostly occur in children aged 2-4 years. Because of a significant increase in the incidence of serotype 19A-related infections, the 13-valent pneumococcal conjugate vaccine (PCV13) was initially introduced in the national immunization program for children 2-5 years of age, prior to the national programs for infants. We have assessed the impact of such vaccination programs in reducing the incidence of invasive pneumococcal disease (IPD) in Taiwanese children.
METHODS: We analyzed the national data on IPDs from the Taiwan Centers for Disease Control between 2008 and 2017. We calculated the incidence rates of IPD and incidence rate ratios (IRRs) between years for different serotypes to estimate the effectiveness of the vaccination programs.
RESULTS: The national catch-up primary vaccination schedule successfully reduced the incidence rate of IPD from 17.8/100 000 in 2012 to 5.5/100 000 in 2017 among children aged 0-5 years. The IRR (2017 over 2012) was 0.31, corresponding to a 69% reduction. A modest herd effect was also observed, with a 37% reduction in the incidence of IPD in elderly people (≥70 years) from 2012 to 2017. The incidence of IPD caused by serotype 19A in children aged 0-5 years was reduced by 32.6-44.3% yearly from 2012 to 2017. In 2015, serogroup 15 outnumbered 19A, to become the leading serotypes in children 0-5 years old.
CONCLUSIONS: Special catch-up vaccination programs starting from children 2-5 years of age with PCV13 have been highly effective in reducing the incidence of IPD, especially as caused by serotype 19A, in Taiwanese children.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  19A; PCV13; Taiwan; invasive pneumococcal diseases; vaccination

Year:  2019        PMID: 30923808     DOI: 10.1093/cid/ciy1127

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan.

Authors:  Chun-Yi Lu; Ching-Hu Chung; Li-Min Huang; Eliza Kruger; Seng-Chuen Tan; Xu-Hao Zhang; Nan-Chang Chiu
Journal:  Cost Eff Resour Alloc       Date:  2020-08-28

2.  Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China.

Authors:  Caixia Wang; Li Su; Qiuling Mu; Xueyan Gu; Xuejun Guo; Xuxia Wang
Journal:  Hum Vaccin Immunother       Date:  2021-02-12       Impact factor: 3.452

Review 3.  A Narrative Review of Pneumococcal Disease in Children in the Philippines.

Authors:  Amgad Gamil; Miriam Y Lalas; Maria Rosario Z Capeding; Anna Lisa T Ong-Lim; Mary Ann C Bunyi; Angelica M Claveria
Journal:  Infect Dis Ther       Date:  2021-04-24

4.  Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan.

Authors:  Wei-Ju Su; Pei-Hung Chuang; Luan-Yin Chang; Hsiu-Yun Lo; Chuen-Sheue Chiang; Ez-Tzu Wang; Chin-Hui Yang
Journal:  BMC Infect Dis       Date:  2021-01-10       Impact factor: 3.090

5.  Genomic Insight into the Spread of Meropenem-Resistant Streptococcus pneumoniae Spain23F-ST81, Taiwan.

Authors:  Yi-Yin Chen; Yu-Chia Hsieh; Yu-Nong Gong; Wei-Chao Liao; Shiao-Wen Li; Ian Yi-Feng Chang; Tzu-Lung Lin; Ching-Tai Huang; Cheng-Hsiu Chiu; Tsu-Lan Wu; Lin-Hui Su; Ting-Hsuan Li; Ya-Yu Huang
Journal:  Emerg Infect Dis       Date:  2020-04       Impact factor: 6.883

6.  Serotype Distribution and Antimicrobial Susceptibility of Streptococcus pneumoniae in Pre- and Post- PCV7/13 Eras, Taiwan, 2002-2018.

Authors:  Chi-Jung Wu; Jui-Fen Lai; I-Wen Huang; Yih-Ru Shiau; Hui-Ying Wang; Tsai-Ling Lauderdale
Journal:  Front Microbiol       Date:  2020-10-22       Impact factor: 5.640

7.  Pneumococcal and Influenza Vaccination Rates and Pneumococcal Invasive Disease Rates Set Geographical and Ethnic Population Susceptibility to Serious COVID-19 Cases and Deaths.

Authors:  Robert Root-Bernstein
Journal:  Vaccines (Basel)       Date:  2021-05-08

8.  Serotype transmission dynamics and reduced incidence of invasive pneumococcal disease caused by different serotypes after implementation of non-pharmaceutical interventions during COVID-19 pandemic.

Authors:  Rajendra Prasad Janapatla; Chyi-Liang Chen; Anna Dudek; Hsin-Chieh Li; Hsin-Ping Yang; Lin-Hui Su; Cheng-Hsun Chiu
Journal:  Eur Respir J       Date:  2021-07-21       Impact factor: 16.671

9.  Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan.

Authors:  Chun-Yi Lu; Ching-Hu Chung; Li-Min Huang; Eliza Kruger; Seng-Chuen Tan; Xu-Hao Zhang; Nan-Chang Chiu
Journal:  Cost Eff Resour Alloc       Date:  2020-08-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.